AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response
单位:[1]Ohio State Univ, Dept Surg, Div Surg Oncol, Wexner Med Ctr, Columbus, OH 43210 USA[2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan, Peoples R China内科学系消化内科华中科技大学同济医学院附属同济医院[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat, Wuhan, Peoples R China儿科学系华中科技大学同济医学院附属同济医院[4]Human Microbiol Inst, New York, NY USA[5]CLS Therapeut, New York, NY USA[6]Harvard Med Sch, Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02115 USA[7]Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Moscow, Russia
Liver metastasis is the main cause of colorectal cancer (CRC)-related death. Neutrophil extracellular traps (NETs) play important roles in CRC progression. Deoxyribonuclease I (DNase I) has been shown to alter NET function by cleaving DNA strands comprising the NET backbone. Moreover, DNase I displays high antimetastatic activity in multiple tumor models. To circumvent long-term daily administrations of recombinant DNase I, we have developed an adeno-associated virus (AAV) gene therapy vector to specifically express DNase I in the liver. In this study, we demonstrate AAV-mediated DNase I liver gene transfer following a single intravenous injection suppresses the development of liver metastases in a mouse model of CRC liver metastasis. Increased levels of neutrophils and NET formation in tumors are associated with poor prognosis in many patients with advanced cancers. Neutrophil infiltration and NET formation were inhibited in tumor tissues with AAV-DNase I treatment. This approach restored local immune responses at the tumor site by increasing the percentage of CD8(+)T cells while keeping CD4(+)T cells similar between AAV-DNase I and AAV-null treatments. Our data suggest that AAV-mediated DNase I liver gene transfer is a safe and effective modality to inhibit metastasis and represents a novel therapeutic strategy for CRC.
基金:
NCI [P30 CA016058]; NIH [1S10OD020006-01]; National Institute of Health [R01-GM95566, R01-CA21486502]; National Natural Science Foundation of China [81700515]
第一作者单位:[1]Ohio State Univ, Dept Surg, Div Surg Oncol, Wexner Med Ctr, Columbus, OH 43210 USA[2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan, Peoples R China
通讯作者:
通讯机构:[1]Ohio State Univ, Dept Surg, Div Surg Oncol, Wexner Med Ctr, Columbus, OH 43210 USA[*1]Dept Surg, Div Surg Oncol, N924 Doan Hall,410 West 10th Ave, Columbus, OH 43210 USA
推荐引用方式(GB/T 7714):
Xia Yujia,He Jiayi,Zhang Hongji,et al.AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response[J].MOLECULAR ONCOLOGY.2020,14(11):2920-2935.doi:10.1002/1878-0261.12787.
APA:
Xia, Yujia,He, Jiayi,Zhang, Hongji,Wang, Han,Tetz, George...&Tsung, Allan.(2020).AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response.MOLECULAR ONCOLOGY,14,(11)
MLA:
Xia, Yujia,et al."AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response".MOLECULAR ONCOLOGY 14..11(2020):2920-2935